2020 ttf alk session qa panel information on the crown trial and firstline lorlatinib
Published 3 years ago • 50 plays • Length 2:36Download video MP4
Download video MP3
Similar videos
-
2:34
2020 ttf alk session qa panel next steps after progression on lorlatinib
-
3:06
2020 ttf alk session qa panel progression on 2nd-gen alk inhibitor if biopsy shows no alk mutation
-
1:43
2020 ttf alk session qa panel reducing dosage on lorlatinib vs switching to a different agent
-
3:46
2020 ttf alk session qa panel the use of an alk tki post chemoradiation for stage 3b lung cancer
-
2:28
2020 ttf alk session qa panel the future of mek inhibitors
-
54:12
alk positive summit 2022: current standards of care and treatment philosophies
-
1:00:16
current research lines in lung cancer
-
30:46
nsclc: alk a rare fusion, yet so many options
-
1:50
2020 ttf alk/ros session qa panel the difference in efficacy of tkis in different patients
-
23:44
2020 ttf alk session raez sequence of alk inhibitors
-
25:07
2020 ttf alk session - lin - tkis for ros1
-
3:24
2020 ttf alk qa panel ros1 clinical trial updates
-
11:02
j-alex trial: should alecensa replace xalkori as first-line alk therapy?
-
4:20
video 2020 ttf alk/ros session qa panel the efficacy of dose reduction or interruption of crizotinib
-
1:39
2020 ttf egfr session qa panel what is the difference between c797s and c797x
-
7:01
case based panel discussion 2.6 alk positive and high pdl1 first line treatment for potentially comp
-
1:57
video 2020 ttf alk/ros session qa panel ros1 patients - chemo after resistance to inhibitor therapy?
-
2:39
grace targeted therapies lung cancer 2021 - return to alectinib -progression on lorlatinib in alk
-
2:21
2020 ttf am session q&a panel treatment options for stk 11 testing and immunotherapy
-
25:10
life after 1st line targeted therapy: what next?